<DOC>
	<DOCNO>NCT01130844</DOCNO>
	<brief_summary>The purpose study determine safety pharmacokinetics MMX mesalamine follow administration child adolescent ulcerative colitis .</brief_summary>
	<brief_title>Safety Pharmacokinetics MMX Mesalamine Children Adolescents With Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>1 . Subjects age 517 year , appropriately obtain informed consent assent . 2 . Subject documented history ulcerative colitis least 3 month . 3 . Subjects currently 5ASA product ( ) contain metabolize mesalamine must stable regimen least 4 week prior first dose investigational medicinal product . 4 . Subjects currently drug regimen , 5ASA product contain metabolized mesalamine , must stable regimen least 4 week prior first dose least 4 week prior first dose investigational medicinal product . 5 . Body weight 18kg82kg inclusive . 1 . Current recurrent disease ( eg cardiovascular , renal , liver , malignancy condition ) could affect colon , action , absorption disposition IMP , clinical laboratory assessment exception exist ulcerative colitis . 2 . Ulcerative Colitis known confine rectum ( isolated rectal proctitis ) . 3 . Any history hepatic impairment moderate severe renal impairment . 4 . The use systemic rectal steroid within last 4 week , immunomodulators within last 6 week , biologics within 6 month , antibiotic use within last 7 day prior first dose investigational medicinal product .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>